NCT05552976 2026-03-17
SUCCESSOR-2
Bristol-Myers Squibb
Phase 3 Active not recruiting
Clinical Trials
10 trialsNCT05050097 2026-03-13
MonumenTAL-2
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05572515 2026-02-13
MajesTEC-9
Janssen Research & Development, LLC
Phase 3 Active not recruiting
NCT05704049 2025-12-29
IZALCO
Sanofi
Phase 2 Active not recruiting
NCT02899052 2025-08-05
Study of Venetoclax in Combination With Carfilzomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma (MM)
AbbVie
Phase 2 Active not recruiting
NCT04458831 2025-06-27
IONA-MM
Sanofi
Active not recruiting
NCT05669989 2025-01-23
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Sanofi
Phase 2 Active not recruiting
NCT03989414 2024-11-29
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
Celgene
Phase 1/2 Active not recruiting
NCT02773030 2024-06-25
A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma
Celgene
Phase 1/2 Active not recruiting
NCT03651128 2022-12-15
KarMMa-3
Celgene
Phase 3 Active not recruiting